Organogenesis Holdings Inc. Files 8-K
Ticker: ORGO · Form: 8-K · Filed: Dec 29, 2025 · CIK: 1661181
| Field | Detail |
|---|---|
| Company | Organogenesis Holdings INC. (ORGO) |
| Form Type | 8-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $1,608,699.84, $3,161,377 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financials, corporate-action
TL;DR
Organogenesis Holdings Inc. filed an 8-K on 12/29/25 for a material agreement and financials, dated 12/22/25.
AI Summary
Organogenesis Holdings Inc. filed an 8-K on December 29, 2025, reporting an entry into a material definitive agreement and financial statements/exhibits. The filing date for the report is December 22, 2025. The company, previously known as Avista Healthcare Public Acquisition Corp., is incorporated in Delaware and headquartered in Canton, MA.
Why It Matters
This 8-K filing indicates a significant event or agreement for Organogenesis Holdings Inc., which could impact its business operations and financial standing.
Risk Assessment
Risk Level: low — This filing is a standard 8-K reporting a material definitive agreement and financial statements, which is routine for public companies.
Key Numbers
- 001-37906 — Commission File Number (SEC File Number for Organogenesis Holdings Inc.)
- 98-1329150 — IRS Employer Identification No. (Tax Identification Number for Organogenesis Holdings Inc.)
Key Players & Entities
- Organogenesis Holdings Inc. (company) — Registrant
- Avista Healthcare Public Acquisition Corp. (company) — Former Company Name
- December 22, 2025 (date) — Date of Earliest Event Reported
- December 29, 2025 (date) — Filing Date
- 85 Dan Road Canton, MA 02021 (address) — Principal Executive Offices
FAQ
What specific material definitive agreement did Organogenesis Holdings Inc. enter into?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item of disclosure, but the specific details of the agreement are not provided in the provided text.
What are the key financial statements or exhibits included in this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item of disclosure, but the specific content of these documents is not detailed in the provided text.
When was Organogenesis Holdings Inc. previously known by another name?
The company was formerly known as Avista Healthcare Public Acquisition Corp., with a date of name change on December 15, 2015.
Where is Organogenesis Holdings Inc. headquartered?
The company's principal executive offices are located at 85 Dan Road, Canton, MA 02021.
What is the SIC code for Organogenesis Holdings Inc.?
The Standard Industrial Classification code for Organogenesis Holdings Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 997 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2025-12-29 16:31:02
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value ORGO Nasdaq Capital Marke
- $1,608,699.84 — e year ended December 31, 2027 equal to $1,608,699.84 and $3,161,377.89, respectively (the "2
- $3,161,377 — ber 31, 2027 equal to $1,608,699.84 and $3,161,377.89, respectively (the "2027 Annual Rent
Filing Documents
- d96437d8k.htm (8-K) — 28KB
- d96437dex101.htm (EX-10.1) — 31KB
- d96437dex102.htm (EX-10.2) — 31KB
- 0001193125-25-335425.txt ( ) — 215KB
- orgo-20251222.xsd (EX-101.SCH) — 3KB
- orgo-20251222_lab.xml (EX-101.LAB) — 17KB
- orgo-20251222_pre.xml (EX-101.PRE) — 11KB
- d96437d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 First Amendment to Lease dated as of December 22, 2025 by and among Organogenesis Inc. and 65 Dan Road SPE, LLC 10.2 First Amendment to Lease dated as of December 22, 2025 by and among Organogenesis Inc. and Dan Road Associates, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Organogenesis Holdings Inc. By: /s/ Lori Freedman Name: Lori Freedman Title: Chief Administrative and Legal Officer Date: December 29, 2025